Details of the Drug Combination

General Information of Drug Combination (ID: DC1ZLN7)

Drug Combination Name

Sunitinib malate RG6046

Indication

Disease Entry	Status	REF
Lymphoid neoplasm	Investigative	[1]

Component Drugs

Sunitinib malate DMN8E5D

RG6046 DMGYWIK

Small molecular drug

N.A.

High-throughput Screening Result

Testing Cell Line: Mak

Zero Interaction Potency (ZIP) Score: 10.915

Bliss Independence Score: 8.048

Loewe Additivity Score: 2.536

LHighest Single Agent (HSA) Score: 10.939

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Sunitinib malate Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[3]
------------------------------------------------------------------------------------

Indication(s) of RG6046

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Investigative	[2]

RG6046 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Modulator	[2]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	JNK-AKT-NF-kB controls P-glycoprotein expression to attenuate the cytotoxicity of deoxynivalenol in mammalian cells. Biochem Pharmacol. 2018 Oct;156:120-134.